Impact of blood volume, tube shaking, and incubation time on reproducibility of Quantiferon-TB gold in-tube assay

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3521-3526

  Gaur, Rajiv L ^a   Pai, Madhukar ^a   Banaei, Niaz ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN;

ADULT; AGE; ANALYTICAL PARAMETERS; ARTICLE; ASSAY; BLOOD VOLUME; COMPUTER PROGRAM; CONTAINER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; GENDER; HEALTH CARE PERSONNEL; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INCUBATION TIME; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; QUALITY CONTROL; QUANTIFERON TB GOLD IN TUBE ASSAY; QUANTITATIVE STUDY; REPRODUCIBILITY; TUBE; TUBE SHAKING; VACCINATION;

ADULT; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TIME FACTORS; TUBERCULOSIS;

EID: 84886484394     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01627-13     Document Type: Article

References (29)

1. World Health Organization. 2010. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.
2. American Thoracic Society. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. Rep. 49(RR-6): 1-51.
3. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. 1999. Isoniazid prophylaxis for tuberculosis in HIV infection: a metaanalysis of randomized controlled trials. AIDS 13:501-507.
4. Menzies D, Pai M, Comstock G. 2007. Meta-Analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med. 146:340-354.
5. Ringshausen FC, Schablon A, Nienhaus A. 2012. Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. J. Occup. Med. Toxicol. 7:6. doi:10.1186/1745-6673-7-6.
6. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. 2012. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 67:62-70.
7. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, MVA85A 020 Trial Study Team. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
8. Diel R, Loddenkemper R, Nienhaus A. 2010. Evidence-based comparison of commercial interferon- release assays for detecting active TB: a metaanalysis. Chest 137:952-968.
9. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm. Rep. 59(RR-5):1-25.
10. Herrera V, Perry S, Parsonnet J, Banaei N. 2011. Clinical application and limitations of interferon- release assays for the diagnosis of latent tuberculosis infection. Clin. Infect. Dis. 52:1031-1037.
11. Pai M, Elwood K. 2012. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges. Can. Respir. J. 19:81-83.
12. Doberne D, Gaur RL, Banaei N. 2011. Preanalytical delay reduces sensitivity of QuantiFERON-TB Gold In-Tube assay for detection of latent tuberculosis infection. J. Clin. Microbiol. 49:3061-3064.
13. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. 2013. Test variability of the Quantiferon-TB Gold In-Tube assay in clinical practice. Am. J. Respir. Crit. Care Med. 187:206-211.
14. Slater M, Parsonnet J, Banaei N. 2012. Investigation of false-positive results given by the QuantiFERON-TB Gold In-Tube assay. J. Clin. Microbiol. 50:3105-3107.
15. Gaur RL, Suhosk MM, Banaei N. 2012. In vitro immunomodulation of a whole blood IFN- release assay enhances T cell responses in subjects with latent tuberculosis infection. PLoS One 7:e48027. doi:10.1371/journal .pone.0048027.
16. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. 2009. Within-subject variability of interferon- assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 4:e8517. doi:10 .1371/journal.pone.0008517.
17. Menzies D, Joshi R, Pai M. 2007. Risk of tuberculosis infection and disease associated with work in health care settings. Int. J. Tuberc. Lung Dis. 11:593-605. Cellestis. 2013. QuantiFERON-TB Gold package insert. Cellestis, Valencia, CA.
18. Rose MV, Kimaro G, Kroidl I, Hoelscher M, Bygbjerg IC, Mfinanga SM, Ravn P. 2013. Evaluation of QuantiFERON microtube, using 0.9 mL blood, for diagnosing tuberculosis infection. Eur. Respir. J. 41:909-916.
19. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Jr, Dye C, Halloran ME. 2009. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. U.S.A.. 106:13980-13985.
20. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, Sanchez MA, Moss AR. 1995. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1:815-821.
21. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP. 2008. Indeterminate test results of T-SPOT.TB performed under routine field conditions. Eur. Respir. J. 31:842-846.
22. Doherty TM, Demissie A, Menzies D, Andersen P, Rook G, Zumla A, VACSEL Study Group. 2005. Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J. Immunol. Methods 298:129-141.
23. Hanekom WA, Hughes J, Mavinkurve M, Mendillo M, Watkins M, Gamieldien H, Gelderbloem SJ, Sidibana M, Mansoor N, Davids V, Murray RA, Hawkridge A, Haslett PA, Ress S, Hussey GD, Kaplan G. 2004. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J. Immunol. Methods 291:185-195.
24. Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, Dockrell HM, Mascart F. 2009. Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One 4:e7972. doi:10.1371/journal .pone.0007972.
25. Dominguez M, Smith A, Luna G, Brady MF, Austin-Breneman J, Lopez S, Yataco R, Moore DA. 2010. The MIT D-lab electricity-free PortaThermTM incubator for remote testing with the QuantiFERON-TB Gold In-Tube assay. Int. J. Tuberc. Lung Dis. 14:1468-1474.
26. Herrera V, Yeh E, Murphy K, Parsonnet J, Banaei N. 2010. Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold In- Tube assay. J. Clin. Microbiol. 48:2672-2676.
27. Catron DM, Rusch LK, Hataye J, Itano AA, Jenkins MK. 2006. CD4T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells. J. Exp. Med. 203:1045-1054.
28. Whitworth WC, Mazurek GH, Goodwin DJ. 2012. Assay parameters affecting variability of Quantiferon-TB Gold In-Tube assay results, abstr A4728. Abstr. Am. Thor. Soc. Int. Conf. American Thoracic Society, San Francisco, CA.
29. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. 1996. Platelets and shear stress. Blood 88:1525-1541